menu
    • menu

    Company profile for Glaukos

    NEW Drugs in Dev: 7
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Our company was the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure which revolutionized the treatment and management of glaucoma. In 2012, we launched our first MIGS device—...
    Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Our company was the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure which revolutionized the treatment and management of glaucoma. In 2012, we launched our first MIGS device—the iStent®—in the United States, followed by our next-generation iStent inject® device in September 2018 and iStent inject® W in September 2020.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GlaukosUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    229 Avenida Fabricante, San Clemente, CA 92653
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.glaukos.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Glaukos Announces The Release Of Its 2025 Sustainability Report
    Glaukos Announces The Release Of Its 2025 Sustainability Report

    16 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-16/glaukos-announces-the-release-of-its-2025-sustainability-report

    PHARMIWEB
    16 Apr 2026
    Share Share
    Glaukos Receives Permanent J-Code For Epioxa
    Glaukos Receives Permanent J-Code For Epioxa

    15 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-15/glaukos-receives-permanent-j-code-for-epioxa

    PHARMIWEB
    15 Apr 2026
    Share Share
    Glaukos to Report Q1 2026 Financial Results April 29
    Glaukos to Report Q1 2026 Financial Results April 29

    08 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-08/glaukos-to-release-first-quarter-2026-financial-results-after-market-close-on-april-29

    PHARMIWEB
    08 Apr 2026
    Share Share
    Glaukos To Showcase Scientific Abstracts At 2026 (ASCRS) Meeting
    Glaukos To Showcase Scientific Abstracts At 2026 (ASCRS) Meeting

    06 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-06/glaukos-to-present-multiple-scientific-abstracts-at-the-2026-american-society-of-cataract-and-refrac

    PHARMIWEB
    06 Apr 2026
    Share Share
    Orsini to Serve as Exclusive Partner for Glaukos' Epioxa
    Orsini to Serve as Exclusive Partner for Glaukos' Epioxa

    23 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/orsini-to-serve-as-single-source-specialty-pharmacy-partner-for-glaukos-epioxa-302719843.html

    PR NEWSWIRE
    23 Mar 2026
    Share Share
    Glaukos Announces Commercial Availability of Epioxa
    Glaukos Announces Commercial Availability of Epioxa

    19 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-19/glaukos-announces-commercial-availability-of-epioxa-a-transformative-innovation-in-interventional

    PHARMIWEB
    19 Mar 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search